UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 22, 2022

NEURONETICS, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)
001-38546
(Commission File Number)
33-1051425
(I.R.S. Employer Identification No.)

3222 Phoenixville Pike, Malvern, PA
(Address of principal executive offices)
19355
(Zip Code)

Registrant’s telephone number, including area code (610) 640-4202

Not applicable.

Securities registered pursuant to Section 12(b) of the Act:

<table>
<thead>
<tr>
<th>Title of each class</th>
<th>Trading Symbol(s)</th>
<th>Name on each exchange on which registered</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock ($0.01 par value)</td>
<td>STIM</td>
<td>The Nasdaq Global Market</td>
</tr>
</tbody>
</table>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On August 22, 2022, Bruce J. Shook notified the board of directors (the “Board”) of Neuronetics, Inc. (the “Company”) of his decision to resign from the Board effective as of October 31, 2022. The Company and Mr. Shook intend to enter into a consulting agreement under which Mr. Shook will provide advisory services to the Board and the Company’s management team through May 31, 2023. In exchange for these services, Mr. Shook will be paid at the rate of $350 per hour and the grant of restricted stock units he received on May 26, 2022 will continue to vest during the term of the consultancy. Mr. Shook’s decision to resign from the Board was not due to any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NEURONETICS, INC.  
(Registrant)

Date: August 26, 2022  
By: /s/ W. Andrew Macan
Name: W. Andrew Macan
Title: SVP, General Counsel, Chief Compliance Officer and Corporate Secretary